Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Rhea-AI Summary
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's President and CEO, Bo Cumbo, along with Chief Medical Officer, Dr. Gabriel Brooks, will engage in a fireside chat on Wednesday, September 18, 2024, at 10:20 am ET.
Investors and interested parties can access a live webcast of the fireside chat through the Events page of the Investors section on the company's website. A replay of the webcast will be available for 30 days following the event. Institutional investors seeking meetings with Solid Biosciences management during the conference are advised to contact their Cantor Fitzgerald representatives.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – SLDB
On the day this news was published, SLDB gained 3.07%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 am ET.
A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conferences may reach out to their Cantor Fitzgerald representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
